Get support that goes beyond medicine.

In addition to the care you receive from your health care team, KEY+YOU provides you and your caregivers with support 24/7 throughout your treatment with KEYTRUDA.

Sign up for support  

For those being treated with KEYTRUDA, support that's here for you, online or on the telephone.

KEY+YOU is here for you, offering:

  • Support Is Available By Telephone for KEYTRUDA® (pembrolizumab)

    Nurse Support

    available by telephone, 24/7.
  • Find Resources To Help With Everyday Needs for KEYTRUDA® (pembrolizumab)


    that can help you with practical, everyday needs, like referrals to transportation for getting to treatment, and child-care or adult-care support.
  • Access Referrals To The Merck Access Program for KEYTRUDA® (pembrolizumab)


    to The Merck Access Program for assistance with paying for treatment and insurance coverage questions.
  • Tips To Help Manage How You Feel During Treatment With KEYTRUDA® (pembrolizumab)

    Tools & Tips

    to help you try to manage how you feel during treatment, and tools to help you manage stress before and after getting a scan.

Sign up for support  

KEY+YOU nurses can provide general information about KEYTRUDA. The information provided through the KEY+YOU Patient Support Program does not take the place of talking to your doctor or health care team. If you have any questions that are specific to your medical condition or treatment, or you’re having side effects, please contact your doctor’s office right away.

To receive more information about KEYTRUDA or sign up for the KEY+YOU Patient Support Program, call 85-KEYTRUDA (855-398-7832).

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma). It also is used to treat a kind of lung cancer called non–small cell lung cancer (NSCLC). KEYTRUDA may be used when your lung cancer has spread (advanced NSCLC) and tests positive for "PD-L1" and your tumor does not have an abnormal "EGFR" or "ALK" gene. It may also be used for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and your lung cancer tests positive for "PD-L1" and, if your tumor has an abnormal "EGFR" or "ALK" gene, you have also received an "EGFR" or "ALK" inhibitor medicine that did not work or is no longer working. It also is used to treat a kind of cancer called head and neck squamous cell cancer (HNSCC). KEYTRUDA may be used when your HNSCC has returned or spread and you have received chemotherapy that contains platinum and it did not work or is no longer working. It is also used to treat a kind of cancer called classical Hodgkin lymphoma (cHL). KEYTRUDA may be used for cHL in adults and children when you have tried a treatment and it did not work or when your cHL has returned after you received 3 or more types of treatment.

PD-L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase.

Important Risk Information About KEYTRUDA® (pembrolizumab)

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough.

Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems (hepatitis). Signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, feeling less hungry than usual, or bleeding or bruising more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine.

Problems in other organs. Signs of these problems may include rash, changes in eyesight, severe or persistent muscle or joint pains, severe muscle weakness, low red blood cells (anemia), shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis).

Infusion (IV) reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out.

Complications of stem cell transplantation that uses donor stem cells (allogeneic) after treatment with KEYTRUDA.These complications can be severe and can lead to death. Your doctor will monitor you for signs of complications if you are an allogeneic stem cell transplant recipient.

Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant; have lung or breathing problems; have liver problems; or have any other medical problems.

If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you become pregnant during treatment with KEYTRUDA.

If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA include feeling tired, itching, diarrhea, decreased appetite, rash, fever, cough, shortness of breath, pain in muscles, bones or joints, constipation, and nausea.

In children, feeling tired, vomiting and stomach-area (abdominal) pain, and increased levels of liver enzymes and decreased levels of salt (sodium) in the blood are more common than in adults.

These are not all the possible side effects of KEYTRUDA. Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit or call

Please read the accompanying Medication Guide for KEYTRUDA and discuss it with your doctor.
The physician Prescribing Information also is available.

Please orient your device to the portrait position to return to the site

Merck Oncology
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This site is intended only for residents of the United States, its territories, and Puerto Rico.
ONCO-1172865-0002 03/17 ONCO-1172867-0002 03/17

E-mail a friend

Share this information about a treatment support program. No personal information (including e-mail addresses) about you or your friend will be collected from this e-mail notification feature offered by Merck.